NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 24th Annual Global Investment ConferencePRNewsWire • 09/08/22
RELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE TENTATIVE SETTLEMENT OF PENDING LITIGATIONPRNewsWire • 08/22/22
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Tentative Settlement of Pending LitigationAccesswire • 08/22/22
NRx Pharmaceuticals, Inc. (NRXP) CEO Stephen Willard on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/15/22
NRx Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Results Focusing on Reactivation & Advancement of its Psychiatry FranchisePRNewsWire • 08/15/22
NRx Pharmaceuticals Announces the Appointment of Stephen Willard, Chief Executive Officer and DirectorPRNewsWire • 07/13/22
Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate RiskAccesswire • 07/04/22
FDA Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for subgroup of Patients with Critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivirPRNewsWire • 07/01/22
NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and BeyondPRNewsWire • 06/23/22
Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for AviptadilAccesswire • 06/13/22
NRx Pharmaceuticals Provides Update on Breakthrough Therapy Designation (BTD) Request for ZYESAMI® (aviptadil)PRNewsWire • 06/11/22
NRx Pharmaceuticals Appoints Seth Van Voorhees, PhD, as Chief Financial Officer and TreasurerPRNewsWire • 06/08/22
Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19Accesswire • 05/26/22
NRx Pharmaceuticals Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) Study of ZYESAMI® (aviptadil) in Critical COVID-19PRNewsWire • 05/26/22
NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. Global Investment ConferencePRNewsWire • 05/19/22
NRx Pharmaceuticals, Inc. (NRXP) CEO Robert Besthof on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/16/22
NRx Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial ResultsPRNewsWire • 05/16/22
NRx Pharmaceuticals Announces Enrollment of First Patient in Phase II Study of Bipolar Depression with Sub-Acute SuicidalityPRNewsWire • 05/12/22